- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | Eli Lilly bets on in vivo cell therapy in $2.4bn Orna Therapeutics buyout | ||
| Mo | Novo sues Hims & Hers despite Wegovy pill offering U-turn | ||
| Mo | Innovent and Lilly to advance new oncology and immunology medicines | ||
| Mo | Novartis starts construction on new research facility in San Diego, US | ||
| Fr | TrumpRx launches to slash drug prices for cash-paying US patients | ||
| Fr | FDA targets illegal drug copies amid latest Hims & Hers/Novo Nordisk flashpoint | ||
| Fr | £1bn London Cancer Hub extension gets go-ahead amid UK life sciences push | ||
| Fr | BMS reports flat revenue growth for full-year 2025 | ||
| Fr | Apotex and Grünenthal sign deal for Nebido Canadian distribution | ||
| Do | Rare paediatric disease voucher programme makes long-awaited US return | ||
| Do | Eisai signs $388m deal for Japanese rights to Henlius' anti-PD-1 mAb | ||
| Do | Everest Medicines and Micot partner on MT1013 commercialisation | ||
| Do | PrimeGen US and DT Cloud Star sign $1.5bn merger agreement | ||
| Mi | GSK oncology and HIV drugs leads to 7% sales rise in 2025 | ||
| Mi | Eli Lilly soars past expectations to hit 45% sales growth in 2025 | ||
| Mi | Novo Nordisk shares tumble 18% after 2026 sales dip warning | ||
| Mi | Relay Therapeutics' zovegalisib secures FDA BTD for advanced breast cancer | ||
| Mi | CEPI and Samsung Biologics partner to boost global vaccine preparedness | ||
| 03.02. | Pfizer sets sights on R&D strategy amid modest FY25 results | ||
| 03.02. | MSD's 2026 sales forecast falls short amid patent losses despite strong Q4 | ||
| 03.02. | SanegeneBio and Genentech sign $1.5bn global RNAi licensing deal | ||
| 03.02. | Aquestive receives FDA CRL for Anaphylm allergic reaction treatment | ||
| 02.02. | Eli Lilly selects Pennsylvania for $3.5bn obesity drugs manufacturing site | ||
| 02.02. | Amgen hands back eczema drug to Kyowa Kirin despite positive late-stage data | ||
| 02.02. | CHMP grants positive opinion for J&J's Akeega use |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.